SCHEMBL5016756

SCHEMBL5016756

OCCn1cnc2cccnc21

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.52
TP53 P04637 1/20 0.52
PABPC1 P11940 1/20 0.52
KMT2A Q03164 1/20 0.52
TDP1 Q9NUW8 1/20 0.43
ADORA2A P29274 1/20 0.42
ADORA1 P30542 1/20 0.42
CYP1A2 P05177 1/20 0.40
GRM2 Q14416 1/20 0.38
EGLN3 Q9H6Z9 1/20 0.38
DPP4 P27487 1/20 0.38
DPP8 Q6V1X1 1/20 0.38
BRD4 O60885 1/20 0.38
CSF1R P07333 1/20 0.38
LMNA P02545 1/20 0.37
ADORA2B P29275 1/20 0.37
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4862100 0.82 MEN1 (0.49) MEN1TP53PABPC1KMT2ATDP1
SCHEMBL4022616 0.82 MEN1 (0.52) MEN1TP53PABPC1KMT2ATDP1
SCHEMBL4019974 0.82 MEN1 (0.49) MEN1TP53PABPC1KMT2ATDP1
SCHEMBL4019976 0.82 MEN1 (0.49) MEN1TP53PABPC1KMT2ATDP1
SCHEMBL10684276 0.82 MEN1 (0.49) MEN1TP53PABPC1KMT2ATDP1
SCHEMBL5015508 0.81 MEN1 (0.51) MEN1TP53PABPC1KMT2ATDP1
SCHEMBL9850780 0.80 EGLN3 (0.63) MEN1TP53PABPC1KMT2ATDP1
SCHEMBL454840 0.79 MEN1 (0.47) MEN1TP53PABPC1KMT2ATDP1
SCHEMBL4258800 0.79 MEN1 (0.47) MEN1TP53PABPC1KMT2ATDP1
SCHEMBL4258804 0.79 MEN1 (0.47) MEN1TP53PABPC1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1313751-B1 NEW MACROLIDES WITH ANTIBACTERIAL ACTIVITY BASILEA PHARMACEUTICA AG (CH) 2008-09-17 EP disclosed
CN-1234718-C New macrolides with antibacterial activity BASILEA PHARMACEUTICA AG (CH) 2006-01-04 CN disclosed
US-6740642-B2 ACTIVE AGAINST GRAM POSITIVE PATHOGENS SUCH AS STAPHYLOCOCCUS AUREUS, STREPTOCOCCUS PNEUMONIAE, GRAM NEGATIVE STRAINS SUCH AS HAEMOPHILUS INFLUENZAE; IMPROVED STABILITY BASILEA PARMACEUTICA AG (CH) 2004-05-25 US disclosed
CN-1464880-A New macrolides with antibacterial activity BASILEA PHARMACEUTICA AG (CH) 2003-12-31 CN disclosed
US-20030199459-A1 Macrolides with antibacterial activity BASILEA PHARMACEUTICA AG, A SWISS COMPANY (CH) 2003-10-23 US disclosed
US-6159975-A Antagonists of gonadotropin releasing hormone MERCK & CO., INC. (US) 2000-12-12 US disclosed
EP-0307014-A1 Anti-allergic 2-(heterocyclyl alkyl) imidazo pyridines and 2-(heterocyclyl alkyl) purines JANSSEN PHARMACEUTICA N.V. (BE) 1989-03-15 EP disclosed
EP-0282133-A2 1-alkyl substituted benzimidazole derivatives JANSSEN PHARMACEUTICA N.V. (BE) 1988-09-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199459-A1 Macrolides with antibacterial activity MRPL21, MRPS22, MRPL12 MEN1 1230/4885TP53 4864/4885PABPC1 4530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.